After months of mixed messaging from the White House, the pharmaceutical industry has gained more clarity on the second Trump administration’s import tariff policy for drugs. While many of the industry’s biggest firms have navigated the trade threat through investment pledges and drug pricing deals, the current landscape remains murkier for small- and mid-sized drugmakers.

In this episode of “The Top Line,” Fierce Pharma’s Fraiser Kansteiner sits down with Chris Young, a principal in KPMG’s trade and customs practice, to discuss the pharma tariff landscape following President Donald Trump’s announcement in early April of a potential 100% tariff on imported drugs. Young explains how the policy could affect smaller drugmakers that haven’t inked high-profile pricing deals with the government and shares best practices for navigating the rapidly evolving U.S. trade environment.

To learn more about the topics in this episode: 
An update on the pharma industry’s reshoring effort
Trump eyes 100% tariff rate for companies that have not struck MFN deals: Bloomberg
Trump's tariff threats, measured by manufacturing
UK signs off on US pharma deal, ensuring tariff reprieve as Britain aims to reattract investments

After months of mixed messaging from the White House, the pharmaceutical industry has gained more clarity on the second Trump administration&rsquo;s import tariff policy for drugs. While many of the industry&rsquo;s biggest firms have navigated the trade threat through investment pledges and drug pricing deals, the current landscape remains murkier for small- and mid-sized drugmakers.
In this episode of &ldquo;The Top Line,&rdquo; Fierce Pharma&rsquo;s Fraiser Kansteiner sits down with Chris Young, a principal in KPMG&rsquo;s trade and customs practice, to discuss the pharma tariff landscape following President Donald Trump&rsquo;s announcement in early April of a potential 100% tariff on imported drugs. Young explains how the policy could affect smaller drugmakers that haven&rsquo;t inked high-profile pricing deals with the government and shares best practices for navigating the rapidly evolving U.S. trade environment.
To learn more about the topics in this episode:&nbsp;
<ul>
<li><a href="https://www.fiercepharma.com/pharma/update-pharma-industrys-reshoring-effort">An update on the pharma industry&rsquo;s reshoring effort</a></li>
<li><a href="https://www.fiercepharma.com/pharma/trump-set-impose-100-tariff-drugs-companies-have-not-struck-mfn-deals">Trump eyes 100% tariff rate for companies that have not struck MFN deals: Bloomberg</a></li>
<li><a href="https://www.fiercepharma.com/manufacturing/trumps-tariff-threats-measured-manufacturing">Trump's tariff threats, measured by manufacturing</a></li>
<li><a href="https://www.fiercepharma.com/pharma/uk-government-signs-us-uk-pharma-deal-ensuring-0-drug-tariffs-britain-looks-re-attract">UK signs off on US pharma deal, ensuring tariff reprieve as Britain aims to reattract investments</a></li>
</ul>

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;